Q2 2026 Cipher Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Epuris revenue grew 14% year-over-year in Q2 2026, with market share expanding to 47.1% in Canada.
- Adjusted EBITDA margins remained strong at 57% for Q2 and 59% year-to-date, with gross margins at 81%.
- SG&A expenses decreased by 16% in Q2 and 30% year-to-date due to operational efficiencies and reduced non-recurring costs.
- The company is debt-free with $9.1 million in cash and access to $90 million in potential financing for growth initiatives.
- A letter of intent with the pan-Canadian Pharmaceutical Alliance is expected to expand Epuris public drug plan coverage, boosting patient access and market share.
- Natroba revenue declined to $6.3 million in Q2 2026 from $7.8 million in Q2 2025, driven by reduced sales volumes to state Medicare programs.
- Total net revenue decreased 10% year-over-year in Q2 2026, impacted by lower Natroba sales and reduced licensing revenue.
- Net income for Q2 2026 fell to $4.0 million from $5.9 million in Q2 2025, partly due to an unrealized foreign exchange loss.
- The company abandoned an advanced acquisition opportunity in Q2 2026, incurring $0.3 million in due diligence costs without a deal.
- Free cash flow was weaker in Q2 due to working capital movements related to payer rebates, which may continue to fluctuate.
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Cipher Pharmaceuticals quarterly conference call for the company's second-quarter 2026 financial results. (Operator Instructions) As a reminder, this conference is being recorded today, Wednesday, August 12, 2026.
On behalf of the speakers that follow, listeners are cautioned that today's presentation and the responses to questions may contain forward-looking statements within the meaning of the Safe Harbor provisions of the Canadian provincial securities laws. Forward-looking statements involve risks and uncertainties, and undue reliance should not be placed on such statements.
Certain material factors or assumptions are implied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. For additional information about factors that could cause results to vary, please refer to the risks identified in the company's Annual Information Form and other filings with Canadian regulatory authorities. Except as required by Canadian securities
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
